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An interesting implication from this 
work is the issue of how mRNAs that 
harbor unspliced U12-type introns 
escape from the nucleus (Figure 1). 
Normally, incompletely spliced RNAs 
are retained in the nucleus until they 
are fully processed or they are targeted 
for degradation. The fate of a newly 
spliced RNA is typically determined 
by the deposition of the exon-junction 
complex (EJC), which assembles over 
newly joined exons immediately after 
splicing and promotes export of cor-
rectly spliced RNA. It is possible that 
the presence of the EJC on multiple 
spliced U2-type exons in U12-con-
taining RNAs is sufficient to mark it 
for export. On the other hand, specific 
factors might exist that recognize the 
partially spliced U12-type RNAs, pre-
vent their degradation, and facilitate 
their nuclear export. Interestingly, this 
situation is akin to the fate of mRNAs 
that retain intronic sequences as part 
of their normal alternative splicing but 
are nevertheless exported.
The results reported by König et 
al. might also have implications for 
how we think about the evolution of 
splicing. The minor spliceosome has 
an early evolutionary origin (Russell 
et al., 2006). U2-type splice junctions 
are far more degenerate than U12-
type junctions, suggesting that U12-
exons were at one point dominant and 
U2-exons evolutionarily derived from 
them. Although provocative, it raises 
the question of whether more, or even 
all, pre-mRNA splicing at one point in 
time occurred in the cytoplasm. The 
correct expression of the more com-
plex genes and genomes of higher 
organisms might have required closer 
coordination of pre-mRNA splicing 
and quality control with transcription, 
therefore favoring migration of the 
splicing reaction to the cell nucleus. 
Thus, the discovery of splicing in the 
cytoplasm provides a glimpse into the 
distant past, while also opening up a 
new vista on the future of pre-mRNA 
splicing.
RefeRences
Denis, M.M., Tolley, N.D., Bunting, M., Schw-
ertz, H., Jiang, H., Lindemann, S., Yost, C.C., 
Rubner, F.J., Albertine, K.H., Swoboda, K.J., et 
al. (2005). Cell 122, 379–391.
Glanzer, J., Miyashiro, K.Y., Sul, J.Y., Bar-
rett, L., Belt, B., Haydon, P., and Eberwine, 
J. (2005). Proc. Natl. Acad. Sci. USA 102, 
16859–16864.
Hall, S.L., and Padgett, R.A. (1996). Science 
271, 1716–1718.
Jurica, M.S., and Moore, M.J. (2003). Mol. Cell 
12, 5–14.
König, H., Matter, N., Bader, R., Thiele, W., and 
Müller, F. (2007). Cell, this issue.
Patel, A.A., and Steitz, J.A. (2003). Nat. Rev. 
Mol. Cell Biol. 4, 960–970.
Russell, A.G., Charette, J.M., Spencer, D.F., 
and Gray, M.W. (2006). Nature 443, 863–866.
Tarn, W.Y., and Steitz, J.A. (1996). Cell 84, 
801–811.
Will, C.L., and Luhrmann, R. (2005). Biol. 
Chem. 386, 713–724.
Will, C.L., Schneider, C., Hossbach, M., Ur-
laub, H., Rauhut, R., Elbashir, S., Tuschl, T., 
and Luhrmann, R. (2004). RNA 10, 929–941.Gaucher Disease:  
forging a new Path to the Lysosome
Gillian M. Griffiths1,*
1Cambridge Institute for Medical Research, Wellcome/MRC Building, Box 139, Addenbrooke’s Hospital, Hills Road, Cambridge 
CB2 0XY
*Correspondence: gg305@cam.ac.uk
DOI 10.1016/j.cell.2007.10.043
Most lysosomal proteins are tagged with a carbohydrate modification that allows their 
recognition and transport to the lysosome. In this issue, Reczek et al. (2007) identify a new 
pathway for protein sorting to the lysosome. They show that β-glucocerebrosidase—the 
lysosomal enzyme defective in patients with Gaucher disease—is delivered to the lyso-
some through its interaction with the transmembrane protein LIMP-2.Lysosomes are acidic intracellular 
organelles where many proteins, lip-
ids, and other macromolecules are 
delivered for degradation by lyso-
somal acid hydrolases. Ever since the 
discovery of lysosomes by de Duve 
and colleagues (de Duve et al., 1955), much of our understanding of how 
proteins are trafficked to this com-
partment and how they function has 
come from studies on a wide range 
of lysosomal storage diseases. In this 
family of genetic diseases, defects in 
the function of the lysosome results Cell 131, Novein mis-sorting or loss of function of 
lysosomal proteins with deleterious 
consequences. In the case of the lys-
osomal storage disease Inclusion-cell 
(I-cell) disease, lysosomal dysfunc-
tion is caused by secretion of most 
lysosomal enzymes from the cell. mber 16, 2007 ©2007 Elsevier Inc. 647
figure 1. Protein sorting to the Lysosome
A simplified scheme of protein sorting to the lysosome that illustrates the differences between 
sorting of lysosomal hydrolases via the mannose 6-phosphate (M6P) receptor and the sorting of 
β-glucocerebrosidase (βGC) via LIMP-2. (Right) Newly synthesized βGC interacts with LIMP-2 
in the endoplasmic reticulum (ER). Dissociation between LIMP-2 and βGC may only occur upon 
reaching the lysosome. Mutations in βGC that lead to loss of interaction with LIMP-2 can account 
for some cases of Gaucher disease. (Left) Lysosomal hydrolases interact with the M6P receptor 
in the trans-Golgi network. The M6P receptor is present on late endosomes but not lysosomes; 
lysosomal hydrolases are thought to dissociate from the receptor in late endosomes. Loss of 
phosphotransferase activity that adds the M6P to lysosomal hydrolases gives rise to I-cell dis-
ease (mucolipidosis type II).Lysosomal hydrolases from patients 
with I-cell disease lack a mannose 
6-phosphate carbohydrate modifica-
tion to their N-linked glycans. This 
finding led to the identification of a 
defective phosphodiesterase in I-cell 
patients that is normally responsible 
for this modification and the mannose 
6-phosphate receptor as the recep-
tor required for sorting the major-
ity of acid hydrolases to lysosomes 
(reviewed in Kornfeld, 1990). This 
example illustrates how studies on 
human genetic diseases have played 
critical roles in our understanding of 
fundamental cell biology.
Not all soluble lysosomal enzymes 
are targeted via the mannose 6-phos-
phate receptor. One of the exceptions 
is β-glucocerebrosidase (βGC), the 648 Cell 131, November 16, 2007 ©2007enzyme that degrades glycosphingo-
lipids and is defective in patients with 
Gaucher disease (the most common 
lysosomal storage disease). Patients 
with I-cell disease have normal levels 
of βGC in their lysosomes, suggest-
ing that this protein is targeted to the 
lysosome by a pathway that is inde-
pendent of the mannose 6-phosphate 
receptor. The nature of this route to 
the lysosome has remained elusive. 
Adding to the puzzle, βGC, a soluble 
enzyme with no evident membrane 
tether, seems to be associated with 
membranes (Rijnboutt et al., 1991). 
Now, a study in this issue from Rec-
zek, Saftig, and colleagues (Reczek 
et al., 2007) provides an answer: βGC 
is recognized by the lysosomal mem-
brane protein, LIMP-2, which targets  Elsevier Inc.βGC to lysosomes. In the absence of 
LIMP-2, βGC is no longer effectively 
packaged and is secreted from the 
cell.
These authors set out to find a 
receptor for βGC by examining pro-
teins that interact with βGC. Using 
affinity chromatography, they iden-
tified a protein called LIMP-2 that 
binds to βGC with remarkable speci-
ficity. LIMP-2 is one of a number of 
transmembrane lysosomal resident 
proteins—such as LAMP-1 and 
LAMP-2—that are found in all cell 
types and are highly glycosylated on 
their luminal domains. LIMP-2 differs 
from LAMP-1 and LAMP-2 because it 
spans the membrane twice, with both 
N and C termini in the cytosol and a 
loop through the lumen of the lyso-
some. Reczek et al. show that βGC 
is recognized by LIMP-2 specifically 
and that in mice lacking LIMP-2, βGC 
is no longer sorted to lysosomes but 
is secreted. Proper lysosomal local-
ization is restored by expression 
of LIMP-2, whereas expression of 
another lysosomal membrane protein, 
LAMP-2, had no effect. The authors 
map the site of interaction between 
βGC and LIMP-2 to a coiled-coil motif 
within the luminal loop of LIMP-2. 
Overexpression of a soluble form of 
this motif, which is itself secreted, 
results in enhanced secretion of βGC 
from cells.
Where in the cell does LIMP-2 
recognize βGC? A number of results 
led the authors to suggest that 
recognition can occur in the endo-
plasmic reticulum (ER). First, they 
show that the association between 
the two proteins is pH dependent 
and is favored at the more neutral 
pH of the ER rather than the acidic 
pH of the lysosome. Second, they 
find that certain βGC mutants that 
are known to be retained in the ER 
can be shifted to the lysosome by 
overexpression of LIMP-2. Third, 
changing the carbohydrate modifi-
cations of LIMP-2, which are added 
after LIMP-2′s transit through the 
ER, had no effect on the associa-
tion between LIMP-2 and βGC. The 
authors also show that addition of 
an ER-retention motif to LIMP-2 
keeps βGC in this compartment.
The results from this new work are 
important not only because of the 
possible therapeutic implications for 
Gaucher disease but also because 
they highlight the fundamental dif-
ference between transport to lyso-
somes mediated by LIMP-2 and by 
the mannose 6-phosphate receptor 
(Figure 1). Recognition of the man-
nose 6-phosphate carbohydrate 
modification on lysosomal hydrolases 
by the mannose 6-phosphate recep-
tor occurs in the trans-Golgi network, 
whereas LIMP-2 recognition of βGC 
can take place in the ER and is appar-
ently carbohydrate independent. Lys-
osomal hydrolases dissociate from 
the mannose 6-phosphate receptor 
in late endosomes as this receptor is 
not present in lysosomes, whereas 
LIMP-2 is present in lysosomes, sug-
gesting that dissociation of βGC from 
LIMP-2 may occur in the lysosome 
itself. It is not clear whether LIMP-2 
might mediate sorting of other pro-Silencing is a critical feature of gene 
regulation in both unicellular and 
higher eukaryotes. In the fission yeast 
Saccharomyces pombe, gene silenc-
ing has been shown unexpectedly to 
involve the RNA interference (RNAi) 
pathway and in particular the RNase 
III enzyme Dicer. In higher eukary-
otes, Dicer is responsible for cutting 
up double-stranded RNA (dsRNA) 
into either small-interfering RNAs 
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There is extensive transcript
antisense transcripts from co
intergenic regions. In this issu
that antisense transcripts, if s
silencing via the recruitment oteins to the lysosome. It is also not 
clear whether LIMP-2 delivers newly 
synthesized proteins, endocytosed 
proteins, or both to lysosomes. How-
ever, the low levels of LIMP-2 found on 
the plasma membrane suggest that it 
may act primarily inside the cell.
These results provide yet another 
example of where the study of a lyso-
somal storage disease has provided 
insights into the fundamental mecha-
nisms controlling protein sorting in cell 
biology. But what insights into Gaucher 
disease do these findings provide? 
One intriguing possibility raised by 
the authors is that some patients with 
Gaucher-like phenotypes might have 
mutations in LIMP-2 that might prevent 
proper sorting of βGC. Further studies 
of LIMP-2-deficient mice will certainly 
provide insights into this possibility. 
The current studies also open up new 
ways in which to understand the loss-
of-function mutations in βGC found in 
patients with Gaucher disease in terms Cell 131, Nove
(siRNAs) or microRNAs that then 
regulate mRNAs through their incor-
poration into the RISC complex. This 
RNA-primed complex targets specific 
mRNAs, either promoting their deg-
radation or inhibiting their translation. 
Instead, in S. pombe, Dicer is associ-
ated with a chromatin-silencing com-
plex (RITS) that is recruited to regions 
of heterochromatin caught in the act 
of low-level transcription from both 
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ion throughout the eukaryoti
ding regions and cryptic unst
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tabilized by exosome impairme
f histone deacetylases.of their recognition and transport by 
LIMP-2. Furthermore, by identifying the 
machinery that governs the secretion of 
βGC, these studies may provide ways 
to improve production of βGC, which 
is used therapeutically to treat patients 
with Gaucher disease. But perhaps 
most importantly these studies high-
light the enormous synergy between 
studies of genetic diseases and our 
understanding of cell biology.
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template strands thereby generating 
dsRNA. Indeed, most other higher 
eukaryotes share this RNAi-induced 
gene-silencing pathway (Grewal and 
Jia, 2007). However, the budding 
yeast S. cerevisiae seems bereft of 
RNAi-mediated gene regulation, as it 
lacks Dicer, Argonaute proteins, and 
RNA-dependent RNA polymerase. 
Yet, gene silencing still occurs in S. 
cerevisiae. So how is it achieved? 
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